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Since breast ultrasonography (US) has been used as an adjunctive screening modality in women 
with dense breasts, the need has arisen to evaluate and monitor its possible harm and benefits in 
comparison with other screening modalities such as mammography. Recently, the fifth edition of 
the Breast Imaging Reporting and Data System published by the American College of Radiology 
has suggested auditing methods for screening breast US. However, the method proposed therein 
is slightly different from how diagnostic performance was calculated in previous studies on 
screening breast US. In this article, the background and core aspects of medical audits of breast 
cancer screening will be reviewed to provide an introduction to the medical auditing of screening 
breast US, with the goal of helping radiologists to understand and identify potential ways to 
improve outcomes. 
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Introduction
Mammography is the only screening modality proven to reduce breast cancer deaths among women 
aged 40 years and older in previous randomized clinical trials [1], despite questions regarding the 
degree of its contribution in improving breast cancer survival in screening settings [2]. However, the 
false-negative rates of mammography can reach 50% in dense breasts [3], and the survival benefit 
of performing mammography is lower in younger women with dense breasts [4], suggesting the 
necessity of developing adjunctive screening modalities. One of the suggested adjunctive modalities 
is ultrasonography (US), for which the incremental cancer detection rates have been reported to be 
2.7 to 4.2 per 1,000 women screened [5,6]. However, several aspects of breast US need to be verified 
before it can be used as the primary screening test for breast cancer.
Although improved survival is the main goal of breast cancer screening programs, obtaining follow-
up data and evaluating the final outcomes requires a lengthy period of time. Therefore, researchers 
have identified several surrogate markers that can be assessed within a short-term follow-up and 
that are also periodically used to monitor the efficacy of screening programs. Medical audits for 
breast cancer screening programs with mammography have been well established [7,8], along with 
legislation making such audits mandatory [9]. However, the medical auditing of screening breast US 
has not been established to date. 
In this article, the background and core aspects of medical audits of breast cancer screening 
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are reviewed to provide an introduction to the medical auditing 
of screening breast US, with the goal of helping radiologists to 
understand and identify potential ways to improve outcomes. 
Background of the Medical Auditing of 
Screening Mammograms
The main purpose of a medical audit, first described in a white paper 
of the U.K. National Health Service in 1989, is to improve patient 
care and outcomes, and the main elements of medical audits are the 
systematic review of care against solid criteria, the implementation 
of changes, and monitoring to confirm improvement [10,11]. 
For mammography, the purpose of a medical audit is to provide 
feedback to facilities and doctors on their performance relative to 
established benchmarks and to improve the overall quality of the 
breast cancer screening program. Several reports have shown the 
effectiveness of medical auditing. One showed improved sensitivity, 
with maintained positive predictive values and an increased number 
of detected cancers, of which most were node-negative, during 2 
years of education and feedback on the audit results were provided 
to radiologists [12]. These results showed improvements in the 
effectiveness of the screening program after the medical audit, 
despite a 50% increase in the use of additional mammographic 
views and sonography. The Breast Imaging Reporting and Data 
System (BI-RADS) was established by the American College of 
Radiology (ACR) in response to communication issues and societal 
concerns about false negatives occurring in the context of a 
nationwide screening mammography program [13-15]. The ACR 
organized the overall structure of mammography reports, including 
assessment categories and the corresponding management 
strategies, supplied benchmarks for mammographic interpretation, 
and furthermore, developed the National Mammography Database 
within the National Radiology Data Registry [15]. 
Medical audits are also necessary because of one serious harm of 
mammography that has recently become an issue: anxiety among 
healthy women due to positive results, of which most will turn 
out to be false positives, with benign results on biopsy [16,17]. It 
has been found that two or three breast cancers will be identified 
among 100 women who receive annual mammograms over the 
course of 10 years. However, of these 100 women, 62 will eventually 
have positive results on their mammograms. Furthermore, seven to 
10 will undergo biopsies with benign pathology results. Therefore, it 
must be determined whether the anxiety arising from the 62 false-
positive results and 10 benign biopsies is inevitable and/or whether 
it is justifiable given the two or three detected breast cancers. 
Searching for ways to lower the excess amount of false-positive 
results and benign biopsies needs to be a part of the medical audit. 
The management of screening mammography should be a constant 
balance between possible harm and benefits; in other words, 
between missing too many cancers and ordering too many biopsies 
and recalls. This balance should be attained through medical 
auditing [9,15,18]. 
Currently, the following basic elements of a medical audit 
are recommended: (1) to track all positive mammograms, (2) to 
correlate the imaging findings with the pathologic results of all 
biopsies performed, and (3) to review known false-negatives within 
12 months of the mammography examination [19]. The majority of 
approximately 250 radiologists in a survey on medical audits agreed 
that audit reports were valuable [20]. However, approximately half 
of the radiologists with less than 10 years of experience and three-
fourths of radiologists in their early 30s replied that they would 
consider ceasing to interpret mammograms if congress mandated 
more intensive auditing requirements without providing funds to 
support the regulation. Thus, conducting more extensive medical 
audits needs both the cooperation of radiologists and the provision 
of sufficient resources [10,20].  
Characteristics and Audit Data of 
Screening Breast US: Comparison with 
Benchmarks for Mammography
Cancer Detection Rate
The role of screening breast US in dense breasts has been studied 
since the early 2000s, and was recently further emphasized by new 
legislation in the United States requiring patients to be notified 
of their breast density after a screening mammography [21]. In 
asymptomatic women, supplementary hand-held US performed by 
radiologists detected 1.8-5.3 additional cancers per 1,000 women 
[5,21-24], and the overall cancer detection rate in supplemental 
screening US was 3.7 per 1,000 women (248 of 66,828) in 10 
single- or multi-center studies [25]. Among these asymptomatic 
women, based on known risk factors, more than three-fifths of 
women with breast cancers detected only by screening US (89 of 
145 women) were found to be at elevated risk in seven studies 
[5,6,18,21,26-29]. Recently, since the implementation of the 
Connecticut Public Act, breast US has been performed on average-
risk women as well, and the cancer detection rate of breast US for 
these women (1.6-2.4 per 1,000 examinations) [21,24,30,31] 
has tended to be lower than the range accepted for screening 
mammography (≥2.5 per 1,000 examinations) [32] and the 
previously observed detection rate in high-risk women (3.7-5.3 per 
1,000 examinations) [5]. As more women without risk factors for 
breast cancer undergo screening breast US, the acceptable range 
of the cancer detection rate needs to be reconsidered for screening 
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breast US [31]. 
Characteristics of Breast Cancers Detected by Screening US
Supplemental breast US improved the detection of mostly node-
negative invasive breast cancer in past studies; approximately 90% 
of breast cancers detected by screening US were stage 0 or I and 
node-negative [25], a much higher percentage than the benchmarks 
for mammography (74.8% and 77.3%, respectively) [32], which 
suggests that breast US can detect early breast cancer. However, the 
positive predictive value of the recommendation for tissue diagnosis 
(PPV2) and the positive biopsy rate (PPV3) showed a large proportion 
of benign pathologic results (3.3%-11.7%), much lower than the 
acceptable range for mammography (20%-40%) [5,21,22,24,31]. 
This suggests that further studies are needed on US interpretation 
and supplemental sonographic techniques to improve the positive 
predictive value of screening breast US. 
The majority of breast cancers detected by breast US (over 90%) 
are known to be invasive, which may suggest that breast US can 
detect early but life-threatening breast cancer [5,33]. However, 
further studies must be performed to generalize these results, 
because the data were also based on study populations with a 
large proportion (70%-100%) of high-risk women, as was the case 
for the cancer detection rates. Recent studies focusing on women 
with an average risk for breast cancer showed much lower rates of 
the detection of invasive cancer (range, 0% to 60%; overall mean, 
50% [5 of 10]) (Table 1) [21,22,24,34]. Moreover, these results 
are also somewhat different from the results of studies on high-
risk women or screening mammography. In particular, the audit 
data for screening breast US among women at an average risk 
for breast cancer demonstrated a higher abnormal interpretation 
rate (25.0%-31.1% vs. 20.9% and 11.5%, respectively), a lower 
positive predictive value for biopsies (3.4%-5.3% vs. 9.0% and 
29.2%, respectively), and more common recommendations for 
short-term follow-up (22.3%-26.6% vs. 11.1%-13.5% and 
3.2%, respectively). These disparities indicate that it is necessary to 
collect various benchmarks for screening breast US according to risk 
stratification.
Proportion of probably benign findings
An abundant proportion of BI-RADS 3 (probably benign) findings 
were found to require additional short-interval follow-up in studies 
on screening US [5,21,22,24]. Because BI-RADS recommends not 
using BI-RADS 3 (probably benign) findings in the interpretation of 
screening mammography, the data for breast US do not correspond 
to what is expected. Although breast US is used as a screening 
modality, it includes a diagnostic component as well as a screening 
component. In fact, no guidelines exist regarding the proportion 
of BI-RADS 3 findings in diagnostic mammography. Therefore, it is 
inevitable that a higher proportion of BI-RADS 3 lesions are found 
through breast US screening than through screening mammography. 
However, recommending additional examinations prior to the next 
screening examination results in patient anxiety and demands 
Table 1. Summary of studies on screening breast ultrasonography according to the risk for breast cancer in comparison with results 
for screening mammography
Variable
Berg et al. 
[5], 2012
Hooley et al. 
[21], 2012
Chang et al. 
[22], 2015
Moon et al. 
[24], 2015
Weigert and 
Steenbergen [34], 2015
Modality MG US US US US US
Risk Increased Increased Increased Average Average Average Not specified
No. of examinations 7,473 7,473 236 614 1,526 2,005 10,282
No. of cancers 59 58 2 1 5 4 24
Yield, per 1000 7.9 7.7 8.5 1.6 3.3 2.0 2.3
Invasive 41/59 (69.5) 53/58 (91.4) 2/2 (100) 0/1 (0) 3/5 (60.0) 2/4 (50.0) 10/21 (47.6)a)
Node-negative 18/41 (43.9) 34/53 (64.2) 2/2 (100) - 3/3 (100) 2/2 (100) -
Abnormal inter-
pretation (recall) rate
306/2,659 (11.5)b) 555/2,659 (20.9)b) 234 (25.0) 431 (28.2) 623 (31.1) 1,310 (12.7)
Short-term follow-up 84/2,659 (3.2)b) 296/2,659 (11.1)b) About 32 (13.5) About 155 
(25.3)c)
340 (22.3) 533 (26.6) 875 (9.0)
Biopsy rate 65/2,659 (2.4)b) 233/2,659 (8.8)b) 66/935 (7.1) 91/1,526 (6.0) 88/2,005 (4.4) 435/10,282 (4.2)
PPV3 19/65 (29.2)
b) 21/233 (9.0)b) 3/66 (4.5) 5/91 (5.3) 3/88 (3.4) 24/435 (5.5)d)
Values are presented as number (%).
MG, mammography; US, ultrasonography; PPV3, positive biopsy rate.
a)Two carcinomas (invasive/uncertain) and one lymphoma were excluded [34]. b)Calculated based on a prevalence screen [5]. c)Inferred from Fig. 2 of the Hooley et al.’s article [21]. 
d)Eight point nine percent if high-risk pathologic lesions are included (39 of 435) [34].
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breast, one for each quadrant, and one for the retroareolar area [37]. 
If a nonbenign breast lesion is found in the screening setting, the 
examination is considered to have become diagnostic. Therefore, the 
screening breast US report should indicate whether only standard 
images were recorded or whether additional (diagnostic) images 
were obtained. Exams with additional images should be considered 
audit-positive for the screening component, regardless of the final 
assessment of breast US (Table 2). Therefore, a positive screening 
includes all subcategories of BI-RADS categories 3, 4, and 5, and 
categories 1 and 2 with more than five images per breast. Negative 
screenings include only BI-RADS categories 1 and 2 with five images 
per breast. Additionally, orthogonal images are not allowed for BI-
RADS category 2, whereas all BI-RADS categories 1 and 2 findings 
were considered as negative screenings regardless of the number of 
images in the previous literature [5,6,18,21,22,24,26,28,30,31,33,
34]. Therefore, the medical audit data will change in correspondence 
with the ACR recommendations. 
Potential Ways to Improve the Outcomes of 
Medical Audits of Breast US
As discussed above, a high short-term follow-up recommendation 
rate and low positive predictive value are characteristics of screening 
breast US [38]; however, several studies have reported reducing 
the number of BI-RADS categories 3 and 4 cases by applying 
supplemental techniques, such as shear-wave elastography (SWE) 
and/or Doppler US [39,40], or by applying strict criteria to the 
imaging findings [41,42]. The addition of SWE and Doppler US to 
B-mode US increased the specificity by more than 45% points in 
non-mass lesions detected by screening US without loss in sensitivity 
(from 10 of 42 to 29 of 42) and helped 65% of patients with BI-
RADS category 4a lesions (19 of 29) avoid unnecessary biopsies [39]. 
By applying the strict criteria of the ACRIN 6666 protocol to imaging 
additional resources. This could be a hurdle in the implementation of 
screening breast US. Therefore, we need to collect data and establish 
benchmarks for the proportion of BI-RADS 3 (probably benign) 
findings in screening breast US. 
Most of the audit data on whole-breast screening US reviewed 
so far have been obtained from previous studies that focused on 
asymptomatic women who had negative mammograms in dense 
breasts, in whom screening US was used as a supplemental modality 
after mammographic information was already obtained, with the 
exception of the American College of Radiology Imaging Network 
(ACRIN) 6666 study [5,23]. Therefore, we need to recognize that the 
currently available data cannot be utilized to evaluate the use of US 
alone to screen for breast cancer.
Medical Audit of Breast US Suggested by 
ACR BI-RADS
The definition of a positive screening result in breast US has 
been continuously debated [35,36]. Based on the principle that 
its definition should be objective and reproducible, and that 
comparisons with other modalities should be possible, a positive 
screening was defined by the ACR as the acquisition of additional 
recorded images such as additional mammographic views, 
regardless of the duration of the examination or whether a second 
opinion was requested [32]. Breast US also includes a diagnostic 
component as well as a screening component. A single report may 
be issued for both components because it would be awkward to 
report the two components of a single US examination separately. 
However, the ACR suggested separate auditing for the screening 
and diagnostic components of combined US examinations [32]. 
According to the protocol of a previous multicenter study, 
which was proposed as a benchmark study in BI-RADS, the image 
requirement for a negative examination is at least five images per 
Table 2. Reference for interpreting biopsy results (screening and diagnostic) according to the ACR BI-RADS
Interpretation
According to the BI-RADS, fifth edition
5 Images for each breast ≥6 Images for either breast
Biopsy-positive Biopsy-negative Biopsy-positive Biopsy-negative
Component: screening (S) or diagnostic (D) S S S D S D
BI-RADS categories 1, 2 Image results Negative Positive Negative Positive Negative
Audit data FN TN TP FN FP TN
BI-RADS category 3 Image results - - Positive Negative Positive Negative
Audit data - - TP FN FP TN
BI-RADS categories 4, 5 Image results - - Positive Positive Positive Positive
Audit data - - TP TP FP FP
ACR, American College of Radiology; BI-RADS, Breast Imaging Reporting and Data System; FN, false negative; TN, true negative; TP, true positive; FP, false positive.
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findings, 18.3% of BI-RADS category 3 lesions (213 of 1,164) were 
retrospectively recategorized as category 2 lesions [42]. Over the 
course of 3 years after education and feedback on audit results were 
provided in clinical practice, the rate of BI-RADS categories 3 to 4a 
was halved (from 22.6%-39.4% to 11.1%-16.0%) and the biopsy 
rates also significantly decreased, from 6.5% to 2.4%, while the 
cancer detection rate of supplemental screening US was maintained 
(2.8 per 1,000 examinations) [41]. 
Conclusion
Medical audits are essential for quality assurance. Therefore, they are 
not optional for breast cancer screening programs, and surrogate 
measures for medical audits of screening breast US need to be 
adjusted and developed. Medical audits will help screening breast 
US to become widely and effectively used as the primary screening 
test with the goal of improving the survival of breast cancer patients.
ORCID: Min Jung Kim: http://orcid.org/0000-0003-4949-1237
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
References
 1. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate 
S, et al. Benefits and harms of breast cancer screening: a systematic 
review. JAMA 2015;314:1615-1634.
 2. Harding C, Pompei F, Burmistrov D, Welch HG, Abebe R, Wilson 
R. Breast cancer screening, incidence, and mortality across US 
counties. JAMA Intern Med 2015;175:1483-1489.
 3. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin 
SH, et al. Breast density as a predictor of mammographic detection: 
comparison of interval- and screen-detected cancers. J Natl Cancer 
Inst 2000;92:1081-1087.
 4. Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, 
et al. Screening for breast cancer: a systematic review to update 
the 2009 U.S. Preventive Services Task Force Recommendation. 
Rockville, MD: Agency for Healthcare Research and Quality, 2016.
 5. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. 
Detection of breast cancer with addition of annual screening 
ultrasound or a single screening MRI to mammography in women 
with elevated breast cancer risk. JAMA 2012;307:1394-1404.
 6. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of 
screening mammography, physical examination, and breast US and 
evaluation of factors that influence them: an analysis of 27,825 
patient evaluations. Radiology 2002;225:165-175.
 7. Farria DM, Monsees B. Screening mammography practice essentials. 
Radiol Clin North Am 2004;42:831-843.
 8. Sickles EA. Quality assurance: how to audit your own mammo-
graphy practice. Radiol Clin North Am 1992;30:265-275.
 9. United States General Accounting Office. Mammography Quality 
Standards Act: X-ray quality improved, access unaffected, but 
impact on health outcomes unknown. GAO/T-HEHS-98-164. 
Washington, DC: US General Accounting Office, 1998.
10. Shaw CD, Costain DW. Guidelines for medical audit: seven 
principles. BMJ 1989;299:498-499.
11. Shaw CD. Medical audit in Britain: what now and what next? Qual 
Assur Health Care 1989;1:61-63.
12. Linver MN, Paster SB, Rosenberg RD, Key CR, Stidley CA, King WV. 
Improvement in mammography interpretation skills in a community 
radiology practice after dedicated teaching courses: 2-year medical 
audit of 38,633 cases. Radiology 1992;184:39-43.
13. Moss M. Spotting breast cancer: doctors are weak link. New York 
Times 2002 Jun 27:Sect. A1, A22.
14. Scott WC. Establishing mammographic criteria for recommending 
surgical biopsy. Report of the Council on Scientific Affairs. Chicago, 
IL: American Medical Association, 1989.
15. Burnside ES, Sickles EA, Bassett LW, Rubin DL, Lee CH, Ikeda DM, 
et al. The ACR BI-RADS experience: learning from history. J Am Coll 
Radiol 2009;6:851-860.
16. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, 
Miglioretti DL. Cumulative probability of false-positive recall or 
biopsy recommendation after 10 years of screening mammography: 
a cohort study. Ann Intern Med 2011;155:481-492.
17. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. 
Harms of breast cancer screening: systematic review to update the 
2009 U.S. Preventive Services Task Force Recommendation. Ann 
Intern Med 2016;164:256-267.
18. Buchberger W, Niehoff A, Obrist P, DeKoekkoek-Doll P, Dunser M. 
Clinically and mammographically occult breast lesions: detection 
and classification with high-resolution sonography. Semin 
Ultrasound CT MR 2000;21:325-336.
19. U.S. Food and Drug Administration. Quality standards and 
certification.s90012 [Internet]. Silver Spring, MD: U.S. Food and 
Drug Administration, 2017 [cited 2017 Jan 17]. Available from: 
http://www.fda.gov/radiation-emittingproducts/mammographyqual
itystandardsactandprogram/regulations/ucm110906.htm.
20. Elmore JG, Aiel lo Bowles EJ, Geller B, Oster NV, Carney 
PA, Miglioretti DL, et al. Radiologists' attitudes and use of 
mammography audit reports. Acad Radiol 2010;17:752-760.
21. Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS, 
Philpotts LE. Screening US in patients with mammographically 
dense breasts: initial experience with Connecticut Public Act 09-41. 
Radiology 2012;265:59-69.
22. Chang JM, Koo HR, Moon WK. Radiologist-performed hand-held 
ultrasound screening at average risk of breast cancer: results from 
Medical audit of screening breast US
e-ultrasonography.org Ultrasonography 36(3), July 2017 203
a single health screening center. Acta Radiol 2015;56:652-658.
23. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, 
Bohm-Velez M, et al. Combined screening with ultrasound and 
mammography vs mammography alone in women at elevated risk 
of breast cancer. JAMA 2008;299:2151-2163.
24. Moon HJ, Jung I, Park SJ, Kim MJ, Youk JH, Kim EK. Comparison 
of cancer yields and diagnostic performance of screening 
mammography vs. supplemental screening ultrasound in 4394 
women with average risk for breast cancer. Ultraschall Med 
2015;36:255-263.
25. Merry GM, Mendelson EB. Update on screening breast 
ultrasonography. Radiol Clin North Am 2014;52:527-537.
26. Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography 
to screen women with mammographically dense breasts. AJR Am J 
Roentgenol 2003;181:177-182.
27. Gordon PB, Goldenberg SL. Malignant breast masses detected only 
by ultrasound: a retrospective review. Cancer 1995;76:626-630.
28. Kaplan SS. Clinical utility of bilateral whole-breast US in the 
evaluation of women with dense breast tissue. Radiology 
2001;221:641-649.
29. Berg WA. Supplemental screening sonography in dense breasts. 
Radiol Clin North Am 2004;42:845-851.
30. Chae EY, Kim HH, Cha JH, Shin HJ, Kim H. Evaluation of screening 
whole-breast sonography as a supplemental tool in conjunction 
with mammography in women with dense breasts. J Ultrasound 
Med 2013;32:1573-1578.
31. Parris T, Wakefield D, Frimmer H. Real world performance of 
screening breast ultrasound following enactment of Connecticut 
Bill 458. Breast J 2013;19:64-70.
32. Sickles EA, D’Orsi CJ. ACR BI-RADS follow-up and outcome 
monitoring. In: D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA, eds. 
ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. 
Reston, VA: American College of Radiology, 2013;1-67.
33. Kelly KM, Dean J, Comulada WS, Lee SJ. Breast cancer detection 
using automated whole breast ultrasound and mammography in 
radiographically dense breasts. Eur Radiol 2010;20:734-742.
34. Weigert J, Steenbergen S. The connecticut experiments second year: 
ultrasound in the screening of women with dense breasts. Breast J 
2015;21:175-180.
35. Berg WA, Mendelson EB. How should screening breast US be 
audited? The patient perspective. Radiology 2014;272:309-315.
36. Sickles EA, D'Orsi CJ. How should screening breast US be audited? 
The BI-RADS perspective. Radiology 2014;272:316-320.
37. Berg WA, Mendelson EB. Technologist-performed handheld 
screening breast US imaging: how is it performed and what are the 
outcomes to date? Radiology 2014;272:12-27.
38. Moon HJ, Kim EK. Characteristics of breast cancer detected by 
supplementary screening ultrasonography. Ultrasonography 
2015;34:153-156.
39. Choi JS, Han BK, Ko EY, Ko ES, Shin JH, Kim GR. Additional 
diagnostic value of shear-wave elastography and color Doppler US 
for evaluation of breast non-mass lesions detected at B-mode US. 
Eur Radiol 2016;26:3542-3549.
40. Lee SH, Chang JM, Kim WH, Bae MS, Seo M, Koo HR, et al. Added 
value of shear-wave elastography for evaluation of breast masses 
detected with screening US imaging. Radiology 2014;273:61-69.
41. Kim SY, Kim MJ, Moon HJ, Yoon JH, Kim EK. Application of the 
downgrade criteria to supplemental screening ultrasound for 
women with negative mammography but dense breasts. Medicine 
(Baltimore) 2016;95:e5279.
42. Chae EY, Cha JH, Shin HJ, Choi WJ, Kim HH. Reassessment and 
follow-up results of BI-RADS category 3 lesions detected on 
screening breast ultrasound. AJR Am J Roentgenol 2016;206:666-
672.
